PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7839044

[Gene therapy--basic principles].

H E Blum
View original source ↗Export metadata ↓

Abstract

Recombinant DNA technology allows the cloning of genes and their expression in vitro. Cloned genes are central to human gene therapy. The principle of gene therapy is based on three different strategies: gene replacement in classic genetic diseases which are caused by a single gene defect that conforms to the rules of Mendelian inheritance; gene augmentation for the treatment of complex genetic diseases by providing the cell with a new function; block of gene expression in acquired genetic diseases such as infections and malignancies.

Explore related subjects

DNA, RecombinantGene AmplificationGene Expression RegulationGenetic TechniquesGenetic TherapyHumansEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H E Blum. 1995-01-10. [Gene therapy--basic principles].. https://pubmed.ncbi.nlm.nih.gov/7839044/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

The recombination hotspot Chi is recognized by the translocating RecBCD enzyme as the single strand of DNA containing the sequence 5'-GCTGGTGG-3'.

The RecBCD enzyme of Escherichia coli functions in the seemingly disparate roles of homologous recombination and the degradation of DNA. Which of these two roles it assumes is regulated by the 8-base recombination hotspot, Chi. Using double-stranded DNA substrates that are heteroduplex at the Chi locus we have established the determinants for Chi recognition. Our results show that an actively translocating RecBCD enzyme requires only the sequence information in the 5'-GCTGGTGG-3'-containing strand to recognize and to be regulated by Chi. Furthermore, the RecBCD enzyme can translocate through DNA heteroduplex bubbles as large as 22 bases, and still recognize a Chi sequence embedded in this region. This implies that recognition of Chi occurs following the unwinding of the DNA.

DNA, Recombinant↗
PubMed1997

Human immunodeficiency virus-1 proviral gene disruption by targeted gene therapy: a hypothetical technique for the elimination of provirus from the infected cells.

A hypothetical technique is proposed for the elimination of all the integrated human immunodeficiency virus-1 provirus from infected cells, based on the developing technology of selective gene excision through homologous recombination. In this technique, a recombinant retroviral packaging cell-line which would produce integrase-Rep78 chimeric protein would be constructed. Replication defective viral stocks would be made from this system which would have recombinant integrase-Rep78 protein packaged along with human immunodeficiency virus-1 long terminal repeat DNA. Since the Rep78 protein, which is a major regulatory protein of adeno-associated virus, has high affinity for human immunodeficiency virus-1 long terminal repeat, it would tether the newly synthesized human immunodeficiency virus-1 long terminal repeat (therapeutic DNA) to the human immunodeficiency virus-1 proviral site in the infected cell. This newly reverse transcribed human immunodeficiency virus-1 long terminal repeat would undergo homologous recombination with the provirus in the infected cells, facilitated by the nicking of the integrase part of the integrase-Rep78 recombinant protein. This selective gene knockout would be accomplished by the combined action of the chimeric integrase-Rep78 protein, where the Rep78 part would help docking of the therapeutic DNA to the proviral integration site and the integrase would provide nicking activity after homologous recombination, resulting in the replacement of human immunodeficiency virus-1 proviral genome with therapeutic DNA.

DNA, Recombinant↗